K
Krimo Bouabdallah
Researcher at Ankara University
Publications - 146
Citations - 3564
Krimo Bouabdallah is an academic researcher from Ankara University. The author has contributed to research in topics: Transplantation & Medicine. The author has an hindex of 24, co-authored 124 publications receiving 2715 citations.
Papers
More filters
Journal ArticleDOI
Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma.
Martin Dreyling,Armando Santoro,Luigina Mollica,Sirpa Leppä,George A. Follows,Georg Lenz,Won Seog Kim,Arnon Nagler,Panayiotis Panayiotidis,Judit Demeter,Muhit Ozcan,Marina Kosinova,Krimo Bouabdallah,Franck Morschhauser,Don A. Stevens,David Trevarthen,Marius Giurescu,Lisa Cupit,Li Liu,Karl Köchert,Henrik Seidel,Carol Peña,Shuxin Yin,Florian Hiemeyer,J. Garcia-Vargas,Barrett H. Childs,Pier Luigi Zinzani +26 more
TL;DR: High response rates to copanlisib were associated with high expression of PI3K/B-cell receptor signaling pathway genes, and this phase II study demonstrated significant efficacy and a manageable safety profile in heavily pretreated patients with relapsed or refractory indolent lymphoma.
Journal ArticleDOI
Graft-Versus-Lymphoma Effect for Aggressive T-Cell Lymphomas in Adults: A Study by the Société Française de Greffe de Moëlle et de Thérapie Cellulaire
Steven Le Gouill,Noel Milpied,Agnès Buzyn,Régis Peffault de Latour,Jean-Paul Vernant,Mohamad Mohty,Marie-Pierre Moles,Krimo Bouabdallah,Claude-Eric Bulabois,Jehan Dupuis,Bernard Rio,Nicole Gratecos,Ibrahim Yakoub-Agha,Michel Attal,Olivier Tournilhac,Didier Decaudin,Jean-Henry Bourhis,Didier Blaise,Christelle Volteau,Mauricette Michallet +19 more
TL;DR: It is concluded that alloSCT is a potentially efficient therapy for NK/T lymphomas and is worth further investigation through prospective clinical trials.
Journal ArticleDOI
Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma.
Martin Dreyling,Franck Morschhauser,Krimo Bouabdallah,Dominique Bron,David Cunningham,Sarit Assouline,Gregor Verhoef,Kim Linton,Catherine Thieblemont,Umberto Vitolo,Florian Hiemeyer,M. Giurescu,J. Garcia-Vargas,Igor Gorbatchevsky,Li Liu,Karl Koechert,Carol Peña,M Neves,Barrett H. Childs,Pier Luigi Zinzani +19 more
TL;DR: Intravenous copanlisib demonstrated promising efficacy and manageable toxicity in heavily pretreated patients with various subtypes of indolent and aggressive malignant lymphoma.
Journal ArticleDOI
Obinutuzumab (GA101) Monotherapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma or Mantle-Cell Lymphoma: Results From the Phase II GAUGUIN Study
Franck Morschhauser,Guillaume Cartron,Catherine Thieblemont,Philippe Solal-Celigny,Corinne Haioun,Reda Bouabdallah,Pierre Feugier,Krimo Bouabdallah,Elina Asikanius,Guiyuan Lei,Michael Wenger,Elisabeth Wassner-Fritsch,Gilles Salles +12 more
TL;DR: Obinutuzumab 1,600/800 mg achieves early steady-state concentration and clinical activity with an acceptable safety profile in relapsed/refractory DLBCL and MCL, supporting further exploration.
Journal ArticleDOI
Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma.
Charles Herbaux,Jordan Gauthier,Pauline Brice,Elodie Drumez,Loic Ysebaert,Hélène Doyen,Luc-Matthieu Fornecker,Krimo Bouabdallah,Guillaume Manson,Hervé Ghesquières,Reza Tabrizi,Eric Hermet,Julien Lazarovici,Anne Thiebaut-Bertrand,Adrien Chauchet,Hélène Demarquette,Eileen M Boyle,Roch Houot,Ibrahim Yakoub-Agha,Franck Morschhauser +19 more
TL;DR: The results show that nivolumab is effective with an acceptable safety profile for patients with relapsed or refractory Hodgkin lymphoma and compared with standard options for this indication.